Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
This article was originally published in The Tan Sheet
Executive Summary
The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."
You may also be interested in...
Warnings In 2019, AERs In 2009: Touchstones Toward Homeopathic Guidance
Priority enforcement areas listed in draft guidance note delivery formats other than oral and topical, such as nasal gel product that was early alarm in FDA's evaluation of safety and efficacy across homeopathic market. Recent warnings also noted in revised draft.
Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO
Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.
Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO
Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.